Lauren Sahakian
Melbourne, VIC, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
APE1/Ref-1 inhibition via APX3330 lowers monocyte/macrophage infiltration without ameliorating the structure and function of dystrophic mdx hindlimb muscles.
Journal: Physiological reports
Published: May 27, 2025
APE1/Ref-1 as a Therapeutic Target for Inflammatory Bowel Disease.
Journal: Biomolecules
Published: September 30, 2023
The role of the gastrointestinal barrier in obesity-associated systemic inflammation.
Journal: Obesity reviews : an official journal of the International Association for the Study of Obesity
Published: January 26, 2023
Molecular Targets to Alleviate Enteric Neuropathy and Gastrointestinal Dysfunction.
Journal: Advances in experimental medicine and biology
Published: December 31, 2022
Dimethyl fumarate modulates the dystrophic disease program following short-term treatment.
Journal: JCI insight
Published: October 04, 2022
Oxidative Stress and Neural Dysfunction in Gastrointestinal Diseases: Can Stem Cells Offer a Solution?
Journal: Stem cells translational medicine
Published: August 16, 2022
Gastrointestinal consequences of lipopolysaccharide-induced lung inflammation.
Journal: Inflammation research : official journal of the European Histamine Research Society ... [et al.]
Published: January 11, 2022
Divergent Adaptations in Autonomic Nerve Activity and Neuroimmune Signaling Associated With the Severity of Inflammation in Chronic Colitis.
Journal: Inflammatory bowel diseases
Published: October 05, 2021
Inhibition of APE1/Ref-1 Redox Signaling Alleviates Intestinal Dysfunction and Damage to Myenteric Neurons in a Mouse Model of Spontaneous Chronic Colitis.
Journal: Inflammatory bowel diseases
Published: February 19, 2020
Eosinophils in Inflammatory Bowel Disease.
Journal: Inflammatory bowel diseases
Published: September 06, 2018
Showing 1-11 of 11
Last Updated: 09/26/2026